1. Home
  2. SLXN vs PLAG Comparison

SLXN vs PLAG Comparison

Compare SLXN & PLAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • PLAG
  • Stock Information
  • Founded
  • SLXN 2008
  • PLAG 1986
  • Country
  • SLXN Israel
  • PLAG United States
  • Employees
  • SLXN N/A
  • PLAG N/A
  • Industry
  • SLXN
  • PLAG Packaged Foods
  • Sector
  • SLXN
  • PLAG Consumer Staples
  • Exchange
  • SLXN NYSE
  • PLAG Nasdaq
  • Market Cap
  • SLXN 7.3M
  • PLAG 6.6M
  • IPO Year
  • SLXN N/A
  • PLAG N/A
  • Fundamental
  • Price
  • SLXN $11.30
  • PLAG $1.71
  • Analyst Decision
  • SLXN Strong Buy
  • PLAG
  • Analyst Count
  • SLXN 1
  • PLAG 0
  • Target Price
  • SLXN $5.00
  • PLAG N/A
  • AVG Volume (30 Days)
  • SLXN 821.0K
  • PLAG 163.7K
  • Earning Date
  • SLXN 08-21-2025
  • PLAG 08-13-2025
  • Dividend Yield
  • SLXN N/A
  • PLAG N/A
  • EPS Growth
  • SLXN N/A
  • PLAG N/A
  • EPS
  • SLXN N/A
  • PLAG N/A
  • Revenue
  • SLXN N/A
  • PLAG $6,066,143.00
  • Revenue This Year
  • SLXN N/A
  • PLAG N/A
  • Revenue Next Year
  • SLXN N/A
  • PLAG N/A
  • P/E Ratio
  • SLXN N/A
  • PLAG N/A
  • Revenue Growth
  • SLXN N/A
  • PLAG N/A
  • 52 Week Low
  • SLXN $0.58
  • PLAG $0.47
  • 52 Week High
  • SLXN $41.85
  • PLAG $5.52
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • PLAG 50.02
  • Support Level
  • SLXN N/A
  • PLAG $1.26
  • Resistance Level
  • SLXN N/A
  • PLAG $2.12
  • Average True Range (ATR)
  • SLXN 0.00
  • PLAG 0.28
  • MACD
  • SLXN 0.00
  • PLAG 0.05
  • Stochastic Oscillator
  • SLXN 0.00
  • PLAG 42.59

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About PLAG Planet Green Holdings Corp.

Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.

Share on Social Networks: